This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of +5.00% and +1.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 2.70% and 3.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
P3 Health Partners (PIII) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
P3 Health Partners (PIII) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last?
by Zacks Equity Research
Veeva (VEEV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 23.26% and 4.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
by Zacks Equity Research
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 4.88% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
by Zacks Equity Research
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.33% and 6.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 7.32% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 5% and 9.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pulmonx Corporation (LUNG) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pulmonx Corporation (LUNG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Down 27.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Pulmonx Corporation (LUNG)
by Zacks Equity Research
Pulmonx Corporation (LUNG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 78.6% in Pulmonx Corporation (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.